Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

While the major indexes are showing major declines this week, United Therapeutics is holding up in a buy zone. Shares are still actionable now.

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

Two biotech stocks, Ligand Pharmaceuticals and United Therapeutics, are showing resilient action in Friday's stock market.

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two companies is the best option for those looking for undervalued stocks?

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.

UTHR shares jump 32% in six months as Tyvaso sales surge, earnings grow and Phase III TETON-2 data open a potential new market in IPF.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the New England Journal of Medicine has published full results of its phase 3 TETON-2 study evaluating the use of nebulized Tyvaso for the treatment of IPF. The publication is available online at NEJM.org. The study met its primary efficacy endpoint, with nebulized Tyvaso demonstrating statistically significant improvement in abso.